Array of excitement at combo's comparison with Roche drug

6 February 2018
2019_biotech_test_vial_discovery_big

USA-based Array BioPharma (Nasdaq: ARRY) and privately-held French drugmaker Pierre Fabre have announced data showing that their combination almost doubles survival in BRAF-positive melanoma compared to the Roche (ROG:SIX) drug Zelboraf (vemurafenib).

The planned analysis of overall survival (OS) from the pivotal Phase III COLUMBUS trial shows that, with treatment with the combination of encorafenib 450mg daily and binimetinib 45mg twice daily, overall survival was 33.6 months, compared to 16.9 months for patients treated with Zelboraf as a monotherapy.

The combination, which is already being reviewed by the US Food and Drug Administration, was generally well-tolerated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology